Ghent University Academic Bibliography

Show Sort by

Your filters: cql: parent exact "BLOOD"

Mark
LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis

Sara El Ashkar, Juerg Schwaller, Tim Pieters (UGent) , Steven Goossens (UGent) , Jonas Demeulemeester, Frauke Christ, Siska Van Belle, Sabine Juge, Nancy Boeckx, Alan Engelman, et al.

(2018) BLOOD. 131(1). p.95-107
Mark
The phase 3 DUO trial : duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Ian W Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Arpad Illes, Gabriel Etienne, Julio Delgado, Bryone J Kuss, Constantine S Tam, Zoltan Gasztonyi, et al.

(2018) BLOOD. 132(23). p.2446-2455
Mark
The EMT transcription factor Zeb2 controls adult murine hematopoietic differentiation by regulating cytokine signaling

Jin Li, Tamara Riedt, Steven Goossens (UGent) , Carmen Carrillo Garcia, Sabrina Szczepanski, Maria Brandes, Tim Pieters (UGent) , Linne Dobrosch, Ines Guetgemann, Natalie Farla (UGent) , et al.

(2017) BLOOD. 129(4). p.460-472
Mark
Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia

Steven Goossens (UGent) , Sofie Peirs (UGent) , Wouter Van Loocke (UGent) , Jueqiong Wang, Mina Takawy, Filip Matthijssens (UGent) , Stefan E Sonderegger, Katharina Haigh, Thao Nguyen, Niels Vandamme (UGent) , et al.

(2017) BLOOD. 129(8). p.981-990
Mark
Real world outcome in a patient cohort with newly diagnosed diffuse large B cell lymphoma

Ciel De Vriendt (UGent) , Philip Vlummens (UGent) and Fritz Offner

(2017) BLOOD. 130(suppl. 1).
Mark
- misc
Novel oncogenic noncoding mutations in T-ALL

Steven Goossens (UGent) and Pieter Van Vlierberghe (UGent)

(2017) BLOOD. 129(24). p.3140-3142
Mark
- conference
- C3
Highly variable frequencies of donor antigen-specific naive cells may dictate the immunogenicity of minor histocompatibility antigens after hematopoietic stem cell transplantation

Anna Kuchmiy (UGent) , Savely Sheetikov, Dmitrii Romaniuk, Anna Postovskaya, Sergey Filkin, Nadia Bykova, Grigory Efimov and Valeriy G. Savchenko

(2017) BLOOD. 130(suppl. 1).
Mark
- conference
- C3
Results from the phase 3 DUOTM trial : a randomized comparison of duvelisib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

Ian W Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Arpad Illes, Gabriel Etienne, Julio Delgado, Bryone Jean Kuss, Constantine S Tam, Zoltan Gasztonyi, et al.

(2017) BLOOD. 130(suppl. 1).
Mark
- conference
- C3
Long term follow-up of the PRIMA study : half of patients receiving rituximab maintenance remain progression free at 10 years

Gilles Andre Salles, John Francis Seymour, Pierre Feugier, Fritz Offner, Armando Lopez-Guillermo, David Belada, Luc Xerri, Reda Bouabdallah, John Catalano, Pauline Brice, et al.

(2017) BLOOD. 130(suppl. 1).
Mark
- conference
- C3
IFM2012-03

Xavier Leleu, Guillemette Fouquet, Lionel Karlin, Brigitte Kolb, Mourad Tiab, Carla Araujo, Nathalie Meuleman, Jv Malfuson, Pascal Bourquard, Pascal Lenain, et al.

(2016) BLOOD. 128(22).

Academic Bibliography

LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis

The phase 3 DUO trial : duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

The EMT transcription factor Zeb2 controls adult murine hematopoietic differentiation by regulating cytokine signaling

Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia

Real world outcome in a patient cohort with newly diagnosed diffuse large B cell lymphoma

Novel oncogenic noncoding mutations in T-ALL

Highly variable frequencies of donor antigen-specific naive cells may dictate the immunogenicity of minor histocompatibility antigens after hematopoietic stem cell transplantation

Results from the phase 3 DUOTM trial : a randomized comparison of duvelisib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

Long term follow-up of the PRIMA study : half of patients receiving rituximab maintenance remain progression free at 10 years

IFM2012-03

Contents

Support

Contact